康方生物(09926.HK)旗下AK104联合AK119治疗晚期实体瘤临床试验完成首例患者给药
康方生物(09926.HK)公布,公司核心自主研发的、全球首创的新型肿瘤免疫治疗双特异性抗体新药Cadonilimab(PD-1/CTLA-4双特异性抗体,研发代号:AK104)及自主研发的新一代CD73单克隆抗体(研发代号:AK119)联合用於治疗晚期实体瘤的I期临床试验完成首例患者给药。这是一项多中心、剂量递增和剂量扩展研究,以评价AK104与AK119联合治疗选定晚期实体瘤的安全性、药代动力学和抗肿瘤活性。
Cadonilimab是公司核心研发管线,主要适应症包括肝癌、宫颈癌、肺癌、胃癌及食管鳞癌等。在宫颈癌、胃癌等多种肿瘤的研究阶段性初步资料显示,Cadonilimab比PD-1和CTLA-4的联合疗法相比,毒性显着降低,具有明显的安全性和疗效优势。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.